The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users
Authors:
- 5 August 2023
- journal article
- research article
- Published by Elsevier in Contraception
- Vol. 128, 110136
Abstract
No abstract availableKeywords
Funding Information
- Eastern Virginia Medical School
- GlaxoSmithKline España (Medicines360)
- Merck
This publication has 23 references indexed in Scilit:
- Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerabilityContraception, 2015
- Weight and body mass index among female contraceptive clientsContraception, 2015
- How can we improve oral contraceptive success in obese women?Expert Review of Clinical Pharmacology, 2014
- Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral ContraceptiveObstetrics & Gynecology, 2013
- Hormonal contraception and venous thromboembolismActa Obstetricia et Gynecologica Scandinavica, 2012
- Metabolism and pharmacokinetics of contraceptive steroids in obese women: a reviewContraception, 2010
- Hormonal contraception and risk of venous thromboembolism: national follow-up studyBMJ, 2009
- A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day: Collaborative Study Group on the Desogestrel-containing Progestogen-only PillThe European Journal of Contraception & Reproductive Health Care, 1998
- A randomized, double-blind study of two combined and two progestogen-only oral contraceptivesContraception, 1982
- RANDOMISED DOUBLE-BLIND TRIAL OF FOUR ORAL PROGESTAGEN-ONLY CONTRACEPTIVESThe Lancet, 1972